Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo radiation approach aims to control advanced lung cancer

NCT ID NCT07565987

Disease control Sponsor: All India Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests whether giving high-precision radiation (SBRT) to the main tumor and nearby lymph nodes, along with standard chemotherapy, can better control stage III non-small cell lung cancer. The trial will enroll 20 adults whose tumors are less than 6 cm and who have not spread to other organs. Researchers will track how long the cancer stays under control and any side effects over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stereotactic body radiotherapy (SBRT) – high-precision radiation to the tumor and lymph nodes
What this could lead to
If successful, this could show that combining SBRT with chemotherapy improves local control and survival for stage III lung cancer patients.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. There is also a risk of radiation-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 or above and less than 75 years. 2. Histologically proven non-small cell lung cancer. 3. Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms. 4. ECOG status 0-1. 5. Available to attend long term follow- up. 6. Written informed consent for treatment. Exclusion Criteria: 1. Metastatic disease. 2. Tumor size \> 6cm. 3. Involved Lymph node size greater than 4 cms \& more than 3 station of lymph nodes involved. 4. Patients with superior vena cava obstruction. 5. Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium. 6. Previous radiotherapy to thorax. 7. Small cell histology. 8. Age\< 18 or \> 75 years. 9. Patients on anticoagulant therapy \& ultra-central cavitary tumors. 10. Poor performance status ECOG 2-3. 11. Immunocompromised states. 12. Viral Markers negative. 13. Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nci, Aiims-Jhajjar

    Jhajjar, Haryana, 124105, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.